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Objective: Cryopreserved aortic allograft can be used for aortic valve replace-
ment in congenital, rheumatic, degenerative, and infected native valve condi-
tions, as well as failed prosthetic valves. This study was conducted to determine
the long-term results of aortic valve replacement with cryopreserved aortic
allografts. Methods: Aortic valve replacement with cryopreserved aortic allo-
grafts was performed in 117 patients from July 1985 until August 1996. All
patients requiring aortic valve replacement regardless of valve disease were
considered for allograft replacement; the valve was preferentially used in
patients under age 55 years and in the setting of bacterial endocarditis. Four
operative techniques involving cryopreserved aortic allografts were used:
freehand aortic valve replacement with 120-degree rotation, freehand aortic
valve replacement with intact noncoronary sinus, aortic root enlargement with
intact noncoronary sinus, and total aortic root replacement. Valve function was
assessed by echocardiography during the operation in 78 patients (66%) and
after the operation in 77 patients (65%). Results: One-hundred eighteen aortic
valve replacements with cryopreserved aortic allografts were performed on 117
patients; mean age was 45.6 years (range 15 to 83 years) and mean follow-up
was 4.6 years (range up to 11 years). Intraoperative echocardiography dis-
closed no significant aortic valve incompetence. There were four operative
deaths (3%) and seven late deaths; freedom from valve-related mortality at 10
years was 9:3% 6 4.55%. New York Heart Association functional status at
latest follow-up was normal in 98 (94%) patients. On postoperative echocar-
diography, 90% had no or trivial aortic valve incompetence. Freedom from
thromboembolism at 10 years was 100% and from endocarditis, 98% 6 2.47%.
Seven (6%) patients required valve explantation, four for structural deterio-
ration. At 10 years, freedom from reoperation for allograft-related causes was
92% 6 3.47%. Conclusions: Aortic valve replacement with cryopreserved aortic
allografts can be performed with low perioperative and long-term mortality.
Most patients have excellent functional status, and reoperation for valve-
related causes is unusual. Aortic valve replacement with cryopreserved aortic
allografts demonstrates excellent freedom from thromboembolism, endocardi-
tis, and progressive valve incompetence. (J Thorac Cardiovasc Surg 1998;115:
371-80)
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Replacement of the aortic valve with an aorticvalve allograft has been shown in several series
to have favorable long-term results in hemodynamic
performance and freedom from reoperation. The
allograft valve is particularly resistant to thrombo-
embolism and is well suited for use in the setting of
active valve infection. Late valve failure, an uncom-
mon event, is most commonly the result of progres-
sive valve incompetence.
Operative techniques for aortic valve replacement
(AVR) with an aortic valve allograft have evolved
since the initial procedures performed indepen-
dently by Barratt-Boyes,1 Ross,2 and Paneth and
O’Brien.3 Current methods now include freehand
valve replacement with 120-degree rotation, free-
hand valve replacement with intact noncoronary
sinus, aortic root enlargement, and aortic root re-
placement by either root inclusion or free-standing
root techniques.
Midterm studies of AVR with cryopreserved aor-
tic valve allografts have shown encouraging re-
sults.4, 5 This study was undertaken to examine the
long-term results of cryopreserved aortic allograft
valves in the aortic position.
Methods
Patient selection. One hundred seventeen patients un-
derwent AVR with a cryopreserved aortic allograft be-
tween July 23, 1985, and August 5, 1996, at LDS Hospital,
Salt Lake City, Utah. The group comprised 100 male and
17 female patients; mean age was 45.6 years (range 15 to
83 years). Patient demographics stratified according to
implant technique are summarized in Table I. One patient
required rereplacement with a second allograft for a total
of 118 valve replacements. Indications for AVR with a
cryopreserved aortic allograft were similar to those for any
patient requiring valve replacement for aortic valve dis-
ease, so that any patient requiring AVR was considered
for inclusion in the study. Cryopreserved valves, however,
are a limited resource, and many more prosthetic valves
than allografts were used for AVR during the study
period. The cryopreserved valve, however, was preferen-
tially used in patients with active bacterial endocarditis, in
patients with contraindications for anticoagulation, and in
patients less than 55 years of age. No patient was excluded
on the basis of age at operation, root deformity, heavy
valve calcification, sinus enlargement, or prior aortic valve
surgery. Coronary artery bypass, mitral valve repair, or
other concomitant procedures were performed as indi-
cated. No form of anticoagulation was used after the
operation in any patient. Patients were followed up pro-
spectively and assessed for valve function and clinical
status from the time of the operation until the current
study closing date of February 1, 1997.
Operative indications. Fifty-one patients (43%) had
congenital aortic valve disease, defined as commissural
fusion and formation of a bicuspid valve. Thirteen patients
(11%) had rheumatic aortic valve disease, defined as a
three-cusp valve with characteristic rolled cusp edges. All
other patients with noninfected, three-cusp valves (18
patients, 15%) were considered to have degenerative
aortic valve disease. Fifteen patients (13%) had clinical
evidence of aortic valve endocarditis. Active bacterial
endocarditis, defined as a positive bacterial culture from
the operative site or the presence of vegetations or
purulence at operation, was identified in 12 patients
(10%). Twenty-one patients (18%) had prior AVRs; five
of these valves were removed for infection.
Allograft valve preservation. Aortic valve allografts
were obtained within 12 hours of donor death by means of
standard, sterile technique by personnel trained by the
transplant organ procurement organization. All allografts
underwent processing and cryopreservation by Cryolife,
Inc. (Kennesaw, Ga.). The allograft was thawed before
implantation, according to protocol.
Operative technique. The methods of allograft valve
implantation used in this series are described below. The
freehand 120-degree rotation technique was initially used
in all patients, but its use was gradually limited to patients
with a small, symmetric aortic root and primarily aortic
valve stenosis. Valve implantation using the freehand
intact noncoronary sinus was later used in most patients
and especially in those with a larger aortic root and aortic
valve incompetence. The root enlargement technique was
used in patients with accompanying subvalvular obstruc-
tion or who required a larger valve than the native root
would accommodate. The total root replacement tech-
nique was used in patients with gross deformity, infection,
or complete destruction of the aortic root. A root inclu-
sion (“mini-root”) technique was used in only one patient
because of our bias against the inclusion of excessive
allograft aorta within the native aorta.
Freehand 120-degree rotation AVR. The freehand 120-
degree rotation AVR technique was performed in 40
patients (34%). After the institution of cardiopulmonary
bypass and aortic occlusion, a transverse aortotomy is
made and extended into the noncoronary sinus. The
diseased valve is excised and an aortic allograft is selected
with an internal diameter approximately 2 mm less than
the measured aortic anulus. Septal myocardium and the
anterior leaflet are removed from the allograft, leaving a 3
to 4 mm rim below the lowest point of valve cusp
attachment. Aortic tissue is removed from all three si-
nuses to leave a 3 to 4 mm margin for suture placement.
The allograft is rotated 120 degrees counterclockwise,
placing the right sinus of the allograft below the left sinus
of the recipient. This positions the allograft septal myo-
cardium against the recipient mitral valve. The graft is
inverted and the lower edge anastomosed to the outflow
tract below the fibrous anulus with continuous 3-0
polypropylene suture. The graft is then returned to its
normal configuration and the allograft sinus margins are
attached to the recipient sinus aorta with continuous 4-0
polypropylene suture.
Freehand intact noncoronary sinus AVR. The freehand
intact noncoronary sinus AVR technique was performed
in 52 patients (44%). The diseased aortic valve is removed
and the anulus sized as described above. Septal myocar-
dium and the anterior leaflet are trimmed from the
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allograft in a similar manner. Aortic tissue is removed only
from the right and left coronary sinuses, leaving the
noncoronary sinus intact. This retains the spatial relation-
ship of two of the commissures and ensures a more
reliable valve implantation. The allograft is positioned in
the anatomic position without rotation and the lower edge
is attached to the outflow tract as previously described.
The right and left allograft coronary sinus margins are
attached to the recipient aorta, and the aortotomy may be
attached to the allograft adventitia or closed over the
noncoronary sinus.
Aortic root enlargement. The aortic root enlargement
technique was performed in 14 patients (12%). The
transverse aortotomy is extended posteriorly and inferi-
orly into the posterior commissure between the left and
noncoronary sinuses, as far as the upper edge of the
anterior leaflet of the mitral valve. The incision may be
extended into the middle portion of the anterior leaflet
to relieve accompanying subvalvular obstruction. Septal
myocardium and the right and left coronary sinus tissue is
trimmed from the allograft, leaving the noncoronary sinus
intact. The allograft mitral anterior leaflet is trimmed
appropriately to match the defect in the recipient non-
coronary sinus or anterior mitral leaflet.
Interrupted 3-0 braided suture is used to attach the
allograft mitral valve tissue to the edge of the recipient
anterior leaflet or to the leaflet itself, effectively widening
the outflow tract. Hemostasis and support are improved
by incorporating a Teflon felt strip into the suture line.
The allograft is inverted and the remainder of the lower
edge attached to the outflow tract as previously described.
The right and left sinuses are reconstructed as noted
above, and the aortotomy is closed directly to the edges of
the allograft noncoronary sinus. If the roof of the left
atrium has been opened, it should be closed with a patch
of pericardium or residual allograft aorta.
Aortic root replacement. Aortic root replacement was
performed in 12 patients (10%). All diseased aorta and
aortic valve tissue is excised, retaining good-sized buttons
of sinus aorta around the coronary arteries. Septal myo-
cardium and the anterior leaflet are trimmed, and the
allograft is attached to the outflow tract without inversion
with interrupted 3-0 polypropylene suture. Hemostasis
and support are improved by means of a Teflon felt or
pericardial “collar,” which is incorporated into the suture
line. The allograft coronary arteries are excised to create
openings approximately 5 mm in diameter, and the recip-
ient coronary arteries are anastomosed directly with con-
tinuous 5-0 polypropylene suture. The distal end of the
allograft is attached in an end-to-end fashion to the
recipient ascending aorta with continuous 4-0 polypro-
pylene suture.
Assessment of valve function. Intraoperative allograft
valve function was assessed clinically before 1989 by
evaluation of closing snap, diastolic thrill, and diastolic
arterial pressure. Beginning in 1989, intraoperative allo-
graft valve function was assessed by surface epicardial
echocardiography or by transesophageal echocardiogra-
phy. Valve incompetence was graded on a scale of 0 to 4,
0 representing no incompetence and 4 representing severe
incompetence.
Postoperative valve function was assessed clinically in
all patients by auscultation and blood pressure mea-
surement. Aortic diastolic murmurs were graded on a
scale of 0 to 4, with 0 representing no audible murmur
and 4 representing a severe murmur. Patients were
questioned regarding functional status and assigned to
an appropriate New York Heart Association functional
class. Echocardiography for indications of possible
valve incompetence was performed at the discretion of
the primary physician or cardiologist. Allograft valve
incompetence was graded on a scale of 0 to 4, the same
as performed during the operation. A valve with no
incompetence was graded as 0, trivial incompetence as
1, mild incompetence as 2, moderate incompetence as
3, and severe incompetence as 4. Valve stenosis was
graded as present or absent.
Data analysis. Postoperative events for all patients
were analyzed by means of Kaplan-Meier methods with
95% confidence intervals (CI). Only four patients had
been followed up for more than 10 years; therefore,
analysis is presented to the 10-year interval. Outcome data
for all patients were then analyzed according to type of
operative procedure. The log-rank test was used to com-
pare patient groups for valve-related mortality, valve
explantation, and structural deterioration.
Results
Mean length of follow-up for all patients was 4.6
years (range up to 11 years); total follow-up for the
series was 515 years. Only seven patients were lost to
follow-up at various time intervals from 2 weeks to 6
years. The data for these patients were included in
all analyses; each patient was censored from the
study at the time of last follow-up.
Table I. Patient demographics by implant technique
Group n
Age (yr)
Gender distribution
Length of follow-up (yr)
Mean Range Mean Range
1. 120-degree rotation 40 47.5 (16-75) 33 M/7 F 6.3 (0-10)
2. Intact NC sinus 52 46.3 (17-73) 48 M/4 F 3.5 (0-11)
3. Root enlargement 14 42.0 (16-83) 9 M/5 F 4.4 (0-9)
4. Root replacement 12 41.2 (15-78) 11 M/1 F 3.8 (0-9)
Total 118 45.6 (15-83) 101 M/17 F 4.6 (0-11)
NC, Noncoronary.
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Intraoperative findings. Thirty-one (26%) pa-
tients had prior cardiac surgery, 21 (18%) for aortic
valve disease. Forty-three (36%) patients had a
concomitant procedure at the time of AVR with a
cryopreserved aortic allograft, which was most com-
monly coronary artery bypass (n 5 13, 11%) or
mitral valve repair (n 5 13, 11%). Mean allograft
valve size was 22.8 mm (range 18 to 30 mm). Aortic
crossclamp time ranged from 66 to 212 minutes with
a mean of 122 minutes. Intraoperative echocardiog-
raphy to assess allograft valve function was per-
formed in 78 (66%) patients; all patients had no or
trivial valve incompetence.
Overall outcomes
Mortality. To date, 11 patients have died. Four of
these patients (3%; 95% CI, 0.9% to 8.5%) died
within 30 days of operation. The remaining deaths
occurred at a mean of 5.7 years (range 4 months to
9 years). Overall survival at 10 years was 76% (95%
CI, 54% to 89%); the linearized rate for all deaths
was 1.4%. Four (3%) deaths were attributable to
valve-related causes; three of these were early
deaths. Valve-related deaths included sudden death
in three patients and death resulting from endocar-
ditis in one patient. Freedom from valve-related
death at 10 years was 93% (95% CI, 76% to 98%),
as illustrated in Fig. 1; the linearized rate for
valve-related death was 0.8%.
Thromboembolism. No patient had a thrombo-
embolic event either in the early postoperative
period or during late follow-up. Freedom from
thromboembolism at 10 years was therefore 100%.
Endocarditis. Staphylococcus aureus endocarditis
developed in one patient 6.5 years after he under-
went allograft root replacement at age 15 years for
congenital bicuspid valve. He was seen at another
institution, where the allograft aortic root was found
to be extensively calcified and was replaced with a
conduit containing a mechanical prosthesis. Free-
dom from endocarditis at 10 years was 98% (95%
CI, 84% to 100%).
Reoperation. Twelve (10%) patients underwent
reoperation, seven (6%) for valve-related causes.
Other causes included coronary artery bypass in
three patients, maze III procedure in one patient,
and second-stage thoracoabdominal aneurysm re-
pair in one patient with aortic dissection. Freedom
from reoperation for any cause was 69% (95% CI,
36% to 87%).
Seven (6%) patients underwent reoperation and
valve explantation, as summarized in Table II. Mean
time to explantation was 5.2 years (range 5 months
to 10 years). The indication for reoperation was
allograft valve incompetence in four patients, endo-
carditis in one patient, technical error in one pa-
tient, and perivalvular leak in one patient. The last
Fig. 1. Freedom from valve-related mortality at 10 years (Kaplan-Meier methods; 95% CI, 76% to 98%).
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patient had a second cryopreserved aortic allograft
implanted and is doing well 4 years later. Freedom
from reoperation for valve-related causes requiring
explantation was 92% (95% CI, 82% to 97%), as
illustrated in Fig. 2; the linearized rate for explan-
tation was 1.4%.
Four (3%) patients had explantation for allograft
valve incompetence resulting from structural dete-
rioration. This occurred at a mean of 6.9 years from
operation (range 2.8 to 10.3 years). Freedom from
valve explantation for structural deterioration was
97% (95% CI, 89% to 99%), as illustrated in Fig. 3;
the linearized rate for structural deterioration was
0.8%.
Functional status. Functional status was normal at
last follow-up in 98 (94%) of 104 surviving patients.
Four (4%) patients were in New York Heart Asso-
ciation class II, two (2%) patients were in class III,
and no patients were in class IV. Functional class for
all patients requiring reoperation was assessed at
the time of the operation.
Allograft valve incompetence. Postoperative clini-
cal assessment of the allografts for evidence of
diastolic murmur was performed in all patients.
Eighty-four (71%) patients had no diastolic mur-
mur, 20 (17%) had grade 1, eight (7%) had grade 2,
and six (5%) had grade 3 murmurs. Three of the
patients with grade 3 murmur and one with grade 2
murmur have undergone allograft valve explanta-
tion. The remaining patients with grade 2 or 3
murmur are clinically doing well.
Postoperative echocardiography was performed
in 77 (65%) patients. Sixty-nine (90%) patients
evaluated had no or grade 1 incompetence, five
Fig. 2. Freedom from valve explantation for any cause at 10 years (Kaplan-Meier methods; 95% CI, 82%
to 97%).
Table II. Allograft valve explants
Age (yr) Gender Years to explant Procedure Cause
16 F 10.3 Freehand 120-degree rotation Structural deterioration
31 M 10.2 Freehand 120-degree rotation Structural deterioration
36 M 4.3 Freehand 120-degree rotation Structural deterioration
48 M 2.8 Freehand 120-degree rotation Structural deterioration
27 M 0.4 Freehand 120-degree rotation Technical error
15 M 4.7 Root replacement Endocarditis
46 M 3.9 Root replacement Perivalvular leak
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(6%) had grade 2, two (3%) had grade 3, and one
(1%) had grade 4. One patient with grade 3 and the
single patient with grade 4 incompetence have un-
dergone valve explantation. The remaining patient
with grade 3 and all patients with grade 2 incompe-
tence are clinically well. Six (8%) patients also had
allograft valve stenosis on echocardiography; four
patients had associated grade 1 incompetence, one
patient had grade 2 incompetence, and one patient
had no valve incompetence.
Subgroup analysis. Kaplan-Meier curves for
valve-related mortality, valve explantation, and
structural deterioration were compared by means of
the log-rank test by operative procedure type. Table
III lists the freedom from valve-related mortality,
freedom from explantation, and freedom from
structural deterioration at 10 years for each group.
Valve-related mortality. Group 1 (120-degree ro-
tation) had the best survival and group 3 (root
enlargement) had the worst survival at 10 years. This
difference was statistically significant (p 5 0.01);
comparisons between the remaining groups were
not statistically significant.
Valve explant. Groups 1 (120-degree rotation)
and 4 (root replacement) contained the only pa-
tients requiring allograft explantation. In group 1,
four patients had explantation for structural deteri-
oration and one for technical error. In group 4, one
patient had explantation for endocarditis and one
for perivalvular leak. No patient in either group 2 or
3, where the noncoronary sinus remains intact,
required allograft explantation. The difference be-
tween groups 1 and 2 was statistically significant
(p 5 0.05), as was the difference between groups 2
and 4 (p 5 0.01).
Structural deterioration. All four allograft explan-
tations for structural deterioration were performed
in group 1 patients, but this difference was not
Fig. 3. Freedom from allograft valve incompetence caused by structural deterioration at 10 years
(Kaplan-Meier methods; 95% CI, 89% to 99%).
Table III. Outcomes at 10 years by implant technique
Group n
Freedom from valve-related
mortality (%)
Freedom from
explantation (%)
Freedom from structural
deterioration (%)
1. 120-degree rotation 40 100 92 94
2. Intact NC sinus 52 98 100 100
3. Root enlargement 14 62 100 100
4. Root replacement 12 92 57 100
Total 118 93 92 97
Data represent Kaplan-Meier 10-year survival or freedom from event. NC, Noncoronary.
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statistically significant when compared with the
other groups.
Comment
AVR with cryopreserved aortic allograft has pro-
duced favorable long-term results at 10 years in this
series of patients. The technique has a low operative
mortality (3%) and late valve-related mortality (also
3%). Overall survival at 10 years was 74%, similar to
the 70% survival at 10 years demonstrated by
O’Brien and associates6 and the 85% survival at 8
years reported by Kirklin and associates.7 The 93%
freedom from valve-related mortality at 10 years was
particularly good in this series.
The cryopreserved aortic allograft continues to
demonstrate excellent freedom from thromboembo-
lism and endocarditis. There were no thromboem-
bolic events even though no anticoagulants were
used. Allograft endocarditis developed in only one
patient in this series, and all 15 patients with active
or inactive endocarditis at operation were cured.
O’Brien and associates6 noted four embolic events
and four cases of endocarditis in their series of 184
patients followed up for 11 years. Kirklin and asso-
ciates7 reported a single incident of thromboembo-
lism and three cases of endocarditis in 178 patients
followed up for 9 years.
Cryopreserved allografts have been shown to have
excellent resistance from structural deterioration,
particularly when compared with fresh refrigerated
valves.8-11 Varying amounts of viable endothelium
and fibroblasts have been found on cellular analy-
sis.12-15 The mechanical properties of cryopreserved
allografts are superior to those of xenograft or fresh
allograft tissue, although inferior to those of native
valve tissue.16, 17 This series of patients provides
clinical follow-up at 10 years with cryopreserved
aortic allografts in which uniform cryopreservation
techniques by a single processor (Cryolife) were
used.
Freedom from reoperation and valve explantation
remains a central issue in assessing the long-term
durability of the cryopreserved aortic allograft. A
total of seven allograft valves were explanted in this
series, four for structural deterioration, one for
perivalvular leak, one for endocarditis, and one for
technical reasons. Freedom from valve explantation
was 92% at 10 years, identical to the 92% 10-year
freedom from reoperation reported by O’Brien and
associates6 and similar to the 86% freedom at 8
years demonstrated by Kirklin and associates.7 Re-
operation for structural deterioration occurs infre-
quently, with a 97% freedom at 10 years in this
series, suggesting excellent performance of cryopre-
served aortic tissues for at least 10 years. Valve
explants appear to have occurred randomly during
the first 10 years. No accelerated phase of valve
explantation has been encountered at this point of
follow-up.
Durability of the cryopreserved aortic allograft
past 10 years remains to be demonstrated conclu-
sively. Valve implantation in young patients is of
particular concern, because xenografts and fresh
allografts have shown accelerated degeneration in
this patient population. O’Brien and associates18
have the only series with follow-up to 15 years;
freedom from structural deterioration with cryopre-
served aortic allograft was 80%. Two of the patients
in this series have had valve explantation just over 10
years after the initial operation, both for structural
deterioration. Both patients were young (16 and 31
years) at the time of allograft implantation.
Use of the cryopreserved aortic allograft in
younger patients is desirable, because no anticoag-
ulation is required, and its excellent hemodynamic
characteristics favor a more vigorous functional
status.19 Analysis of patients under the age of 50
years in this series was done; the mean age of these
younger patients was 33.8 years and mean follow-up
was 4.7 years (range up to 11 years). Only one
valve-related death occurred in this group, but all
four explants for structural deterioration occurred
in this group of younger patients.
Considerable debate continues over the preferred
operative technique for replacement of the aortic
valve with a cryopreserved aortic allograft. Clearly,
no single technique is applicable to all types of aortic
root disease, as reviewed by O’Brien and associ-
ates.20 Some authors favor aortic root replacement
over subcoronary implantation to more consistently
maintain allograft geometry as a means of reducing
valve insufficiency.21-23 Others recommend careful
subcoronary implantation to achieve optimal re-
sults.24, 25 Still other series have demonstrated no
conclusive evidence to favor one technique over
another.26-29 Nevertheless, in today’s practice, intra-
operative echocardiography should assure that a
competent aortic valve is achieved at operation and
perhaps should allow meaningful comparison of late
results related to operative technique.
Root replacement with cryopreserved aortic allo-
graft retains the allograft valve in its native position,
which helps avoid valvular distortion during implan-
tation. The operation may be technically easier and
avoids long-term changes in the native aortic root,
such as dilatation, which could affect the function of
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a freehand implanted allograft. The allograft aorta,
however, always undergoes calcification as time
passes, with progressive shrinkage and hardening.
This places undue stress on the allograft valve,
which may also distort the otherwise intact valve
leaflet tissue. Mini-root or intraluminal (inclusion)
cylinder techniques retain the patient’s native aortic
tissue, but the space between the graft and the
natural aortic root may be redundant or too small,
resulting in kinking or distortion of the graft when
the aorta is closed. Conversely, freehand techniques
are technically more demanding and require precise
positioning of the valve commissures to prevent
distortion of the leaflets. Reimplantation of the
coronary arteries, however, is not necessary, and the
patient’s aortic tissue is retained, providing more
flexible support for the graft and less leaflet stress.
Removal of most of the graft aorta should reduce
the degree of long-term calcification in the root.
This series used four separate techniques for
AVR: freehand 120-degree rotation, freehand intact
noncoronary sinus, root enlargement, and root re-
placement. The freehand 120-degree rotation tech-
nique was used initially but has been largely aban-
doned in favor of the freehand intact noncoronary
sinus technique developed by Ross.30 Leaving the
noncoronary sinus intact retains the anatomic rela-
tionship of two of the three commissures, making
valve implantation more consistent, reproducible,
and reliable. Both operations had low valve-related
mortality in this series, with no deaths in group 1
and one valve-related death in group 2 (Table IV).
However, all explantations for structural deteriora-
tion occurred in the 120-degree rotation group. The
intact noncoronary sinus technique was therefore
clinically superior to the 120-degree rotation tech-
nique for freedom from valve explantation.
Root enlargement with cryopreserved aortic allo-
graft also retains the noncoronary sinus and resulted
in no explants among 14 patients. No statistically
significant difference was observed between this
group and the intact noncoronary sinus group for
either outcome. Although the number of patients
was considerably smaller than in the intact noncoro-
nary sinus group (52 patients), the techniques have
the same long-term results and for practical pur-
poses may be considered equivalent.
In this series, valve-related mortality was not
significantly different between the intact noncoro-
nary sinus group and the root replacement group,
with one death in each group (Table IV). There was
also no significant difference in structural deteriora-
tion between the groups, because no valves required
reoperation for this event in either group. Two
valves in the root replacement group required ex-
plantation for other causes, one for endocarditis and
one for perivalvular leak. In the latter patient, the
allograft had been implanted as an inclusion root.
Although the allograft valve cusps were structurally
intact, the graft had pulled away from the aorta,
which was much larger. The allograft was excised
and a second cryopreserved aortic allograft was
implanted by means of the intact noncoronary sinus
technique after the natural aortic root was remod-
eled; the patient is clinically well at 4 years’ follow-
up. The intact noncoronary sinus technique was
statistically superior when compared with the root
replacement technique for freedom from valve ex-
plantation. Importantly, this difference was evident
despite the smaller number of patients and shorter
follow-up in the root replacement group. In addi-
tion, when patients receiving allografts with an
intact noncoronary sinus (combined groups 2 and 3)
were compared with patients in the root replace-
ment group for freedom from explantation, the
difference was highly statistically significant (p 5
0.005).
In summary, this series demonstrates that the
intact noncoronary sinus technique has favorable
results for valve-related mortality, freedom from
valve explantation, and freedom from structural
deterioration. AVR with the cryopreserved aortic
allograft demonstrated excellent freedom from
valve-related mortality and reoperation for all tech-
niques, and the incidence of endocarditis was neg-
ligible. Thromboembolism was nonexistent and pa-
tients did not require anticoagulation of any type.
The cryopreserved aortic allograft also demon-
strated excellent freedom from structural deteriora-
tion and, when required, all explants for structural
deterioration occurred in the freehand 120-degree
rotation group. AVR with cryopreserved aortic al-
lograft results in a well-functioning valve in more
Table IV. Selected events by implant technique
Group n
Valve-
related
deaths Explants
Structural
deterioration
1. 120-degree rotation 40 0 5 4
2. Intact NC sinus 52 1 0 0
3. Root enlargement 14 2 0 0
4. Root replacement 12 1 2 0
Total 118 4 7 4
NC, Noncoronary.
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than 90% of patients at 10 years without need for
anticoagulation and no evidence for accelerated
valve degeneration.
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Discussion
Dr. R. Scott Mitchell (Stanford, Calif.). Dr. Doty, we are
indebted to you and your colleagues for reporting United
States data with a standardized cryopreservation tech-
nique that begin to approach the results of Mr. O’Brien.
Many of these issues have now been resolved: Valve
performance is excellent, including resistance to infection
and freedom from thromboembolism. Data are fairly
good out to 10 years, although the numbers become
somewhat small in those last 2- or 3-year intervals. Un-
fortunately, inasmuch as four implantation techniques
were used, it is difficult to rigorously establish differences
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between these various techniques. Questions regarding
valve durability remain, especially for the younger patients
less than 50 years old. However, it is encouraging that no
trends have yet become apparent in your data; such trends
were certainly obvious with the pig valves by 8 or 9 years.
The favored techniques seemed to be the freehand tech-
nique with intact coronary sinus and root replacements,
both of which minimize the potential for distortion of the
valve apparatus. This leads to my first question. Do you
think that this preservation of the relationships with the
intact sinotubular ridge and the valve commissures is
important for maximal prolongation of leaflet function?
Dr. Doty. Yes, we do. We prefer the intact noncoronary
sinus technique for a couple of reasons. First, this method
reduces the amount of allograft aorta that is actually
implanted into the patient; we know that the allograft
calcifies with time, and eventually the tube becomes rigid.
There has been some evidence from the literature that
exact allograft sizing using a root replacement technique
may result, over time, in a small loss of coaptation of the
valve leaflets at 8 to 10 years. With the intact noncoronary
sinus technique, a small amount of redundant leaflet
tissue is implanted; therefore, because the allograft may
shrink with time, we have extended coaptation of the
leaflets.
Dr. Mitchell. That is an important point. Obviously,
sizing is critical. We have noticed that few homografts
greater than 23 mm are available. Can you offer some
advice on how much annular size can be reduced to
implant an available homograft?
Dr. Doty. We try not to reduce the size of the anulus;
typically 2 or 3 mm can be obtained by simply stitching the
commissure. That has been a problem with allografts all
along—first, availability of the allografts and, second, the
size restriction—which is the reason we have had to
reserve our valve selection for patients.
Dr. Mitchell. My third question stems from our own
experience. Dr. Shumway, in the early days, had a signif-
icant number of patients in whom fresh allograft from
transplant recipients and unsuitable donor hearts was
implanted. I did not implant any of those allografts, but I
have removed some, and they are extensively calcified.
Very little aorta remains. What do you do in terms of
trying to reconstruct the aortic tissues?
Dr. Doty. If we need to reoperate on a patient who has
undergone root replacement, we prefer to open the
allograft and insert a prosthetic valve. As you have
mentioned, the options are rather limited if primary root
replacement has been done; that is why we prefer the
intact noncoronary sinus technique. It is purely valve
implantation, and options at reoperation may then include
prosthetic implantation, implantation of additional ho-
mograft or allograft, Ross procedure, or implantation of a
xenograft.
Dr. Mitchell. One of your indications for reoperation
was the appearance of coronary disease. Was any of this
coronary ostial disease, maybe attributable to the reim-
planted coronary button?
Dr. Doty. I do not have that information; I cannot
comment on that, Dr. Mitchell.
Dr. Mitchell. Last, how do you account for the greater
fallibility of grafts in which you had to do anulus enlarge-
ments?
Dr. Doty. We have not been able to account for that.
The root enlargement group comprised only 14 patients,
and two of those required explantation. At this point, we
have no explanation for that.
Dr. Vaughn A. Starnes (Los Angeles, Calif.). Did you
see any age-related differences in your implants? Your
data look very good, but we all know that homografts
deteriorate in the very young.
Dr. Doty. Yes, we did, Dr. Starnes. Of the seven grafts
that were explanted, five were from patients who were
younger than 40 years old. One of our patients was 15
years old, and that patient had explantation, so we did
notice more of the explants in the younger age group.
Dr. Starnes. Can you offer some recommendations
about homograft replacement in terms of age-related
factors?
Dr. Doty. Yes. As a result of this study, we have altered
our indications for use of the homograft; in particular, we
try to avoid using homografts in the younger age group
and have now begun using the autograft procedure in-
stead. We now typically use the homografts in the follow-
ing situations: for endocarditis, because all of our patients
were cured of endocarditis when treated with an allograft;
for extensive root destruction whether it be from endo-
carditis or other processes; for patients who are older and
do not have an expected life span of more than 10 or 15
years; and also in contraindications for anticoagulation.
Dr. Starnes. Would you say younger is less than 50, less
than 45, less than 40?
Dr. Doty. We are saying less than 45.
Dr. Starnes. In that group, less than 45, would you use
the Ross procedure?
Dr. Doty. That is correct.
Dr. Fareed Khouqeer (Houston, Tex.). Dr. David Clarke
was experimenting with the use of cyclosporine (INN:
ciclosporin) in 1987 or 1986. Are any of your patients
using immunosuppressive drugs?
Dr. Doty. No, we have not used steroids, cyclosporine,
azathioprine, or ibuprofen, as has been recommended by
others. According to the current literature, endothelium
seems to be the most immunogenic portion of the allo-
graft, and the cryopreservation technique probably de-
stroys the vast majority of the endothelium. In addition,
when the allograft is being implanted, it is placed over the
index finger of the surgeon. During manipulation, most of
the remaining endothelium is probably rubbed off, so we
have not used any form of immunosuppression on our
patients.
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